Dishman Carbogen Amcis Ltd (DCAL) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1002833,
    "name": "Dishman Carbogen",
    "stock_name": "Dishman Carbogen",
    "full_name": "Dishman Carbogen Amcis Ltd",
    "name_url": "stocks-analysis/dishman-carbogen",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "231.15",
    "chg": 15.75,
    "chgp": "7.31%",
    "dir": 1,
    "prev_price": "215.40",
    "mcapval": "3,624.04 Cr",
    "mcap": "Small Cap",
    "scripcode": 540701,
    "symbol": "DCAL",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE385W01011",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "3.89 lacs",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/dishman-carbogen-1002833-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Dishman Carbogen Amcis Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dishman-carbogen-amcis-faces-mildly-bearish-momentum-amid-technical-downgrade-3742970",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/DishmanCarbogen_technicaldot_3742970.png",
        "date": "2025-12-03 08:08:09",
        "description": "Dishman Carbogen Amcis, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflecting a complex interplay of market forces. Recent evaluation adjustments indicate a transition from a sideways trend to a mildly bearish stance, underscoring the nuanced signals from various technical indicators."
      },
      {
        "title": "Dishman Carbogen Amcis: Analytical Perspective Shifts Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/dishman-carbogen-amcis-downgraded-to-sell-amid-mixed-fundamentals-and-technical-weakness-3740733",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/DishmanCarbogen_mojoScore_3740733.png",
        "date": "2025-12-02 08:51:26",
        "description": "Dishman Carbogen Amcis, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market assessment following a detailed evaluation of its quality, valuation, financial trends, and technical indicators. This article explores the factors influencing the recent changes in the company’s analytical perspective, providing investors with a comprehensive understanding of its current standing."
      },
      {
        "title": "Dishman Carbogen Amcis Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dishman-carbogen-amcis-faces-technical-momentum-shift-amid-mixed-market-signals-3740320",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/DishmanCarbogen_technicaldot_3740320.png",
        "date": "2025-12-02 08:11:12",
        "description": "Dishman Carbogen Amcis, a key player in the Pharmaceuticals & Biotechnology sector, is exhibiting a notable shift in its technical momentum as recent evaluation adjustments reflect a transition from mildly bullish to sideways trends. This development comes amid a complex interplay of technical indicators, including MACD, RSI, moving averages, and Bollinger Bands, which collectively paint a nuanced picture of the stock’s near-term trajectory."
      },
      {
        "title": "How has been the historical performance of Dishman Carbogen?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-dishman-carbogen-3739337",
        "imagepath": "",
        "date": "2025-12-01 23:27:11",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Operating Performance</strong></p>\n<p>Over the seven-year period ending March 2025, Dishman Carbogen’s net sales demonstrated a generally upward trend, increasing from ₹2,058.60 crores in 2019 to ₹2,711.50 crores in 2025. This represents a compound growth trajectory, with notable acceleration from 2021 onwards. Total operating income mirrored this pattern, reflecting the absence of other operating income throughout the period.</p>\n<p>Operating profit before depreciation, interest, and tax (PBDIT) excluding other income showed volatility. It declined from ₹551.90 crores in 2019 to a low of ₹274.35 crores in 2021, before recovering to ₹468.94 crores in 2025. Including other income, operating profit (PBDIT) followed a similar pattern, peaking at ₹605.72 crores in 2019 and dipping to..."
      },
      {
        "title": "Dishman Carbogen Sees Revision in Market Evaluation Amid Mixed Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/dishman-carbogen-upgraded-from-sell-to-hold-by-marketsmojo-on-26-may-2025-3735320",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/DishmanCarbogen_mojoScore_3735320.png",
        "date": "2025-11-28 10:04:56",
        "description": "Dishman Carbogen, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a nuanced shift in its financial and technical outlook. This adjustment follows a detailed reassessment of the company’s quality, valuation, financial trends, and technical indicators, offering investors a fresh perspective on its current standing."
      },
      {
        "title": "Why is Dishman Carbogen falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-dishman-carbogen-fallingrising-3727023",
        "imagepath": "",
        "date": "2025-11-25 01:28:44",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Performance</strong></p>\n<p>Dishman Carbogen’s stock has been under pressure over the past month, registering a steep decline of 19.28%, in stark contrast to the Sensex’s modest gain of 0.82% during the same period. The one-week performance further emphasises this trend, with the stock falling 8.83% compared to the Sensex’s near-flat movement. Year-to-date, the stock is down 15.41%, while the benchmark index has advanced by 8.65%. This divergence highlights the stock’s recent struggles relative to the broader market.</p>\n<p>On the day in question, the stock underperformed its sector by 2.96%, continuing a two-day losing streak that has seen a cumulative decline of 6.68%. Intraday, the share price touched a low of ₹228.15, down 3.75%, with heavier trading volu..."
      },
      {
        "title": "Why is Dishman Carbogen falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-dishman-carbogen-fallingrising-3681497",
        "imagepath": "",
        "date": "2025-11-07 23:37:52",
        "description": "As of 07-Nov, Dishman Carbogen Amcis Ltd is experiencing a decline in its stock price, currently at Rs 249.00, reflecting a decrease of Rs 18.45 or 6.9%. The stock has underperformed its sector by 6.56% today and has been on a consecutive downward trend for the last two days, resulting in a total drop of 16.2%. Additionally, the stock has shown high volatility with an intraday range of Rs 25.6 and has traded more volume closer to its low price. Despite a strong performance over the past year with a return of 29.02% and positive results in the last three quarters, including a significant increase in profits, the recent price movement indicates a struggle against short-term pressures.\n\nBroader market context shows that while Dishman Carbogen has outperformed the BSE500 over the long term, its short-term performance has been significantly weaker, with a 1-week decline of 14.65% compared to the Sensex's minor d..."
      },
      {
        "title": "Dishman Carbogen Amcis Hits Day Low at Rs 245.25 Amid Price Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dishman-carbogen-amcis-hits-day-low-at-rs-24525-amid-price-pressure-3678992",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/DishmanCarbogen_priceRelatedfactors_3678992.png",
        "date": "2025-11-07 09:42:26",
        "description": "Dishman Carbogen Amcis saw a notable decline on November 7, 2025, with the stock dropping significantly and reaching an intraday low. This marks a continuation of a downward trend over two days, alongside high volatility. In contrast, the broader market, represented by the Sensex, experienced a smaller decline."
      },
      {
        "title": "Is Dishman Carbogen overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-dishman-carbogen-overvalued-or-undervalued-3678104",
        "imagepath": "",
        "date": "2025-11-07 08:12:37",
        "description": "As of 6 November 2025, Dishman Carbogen's valuation grade has moved from very attractive to attractive, indicating a shift in market perception. The company is currently considered fairly valued. Key ratios include a PE ratio of 28.07, an EV to EBITDA of 10.39, and a Price to Book Value of 0.72. \n\nIn comparison to its peers, Dishman Carbogen's PE ratio is lower than that of Sun Pharma, which stands at 35.02, and significantly lower than Divi's Lab at 79.09. However, it is on par with Cipla, which has a PE of 22.27, and Dr. Reddy's Labs at 17.42. Notably, Dishman Carbogen has outperformed the Sensex over the past year with a return of 37.05% compared to the Sensex's 3.65%, reinforcing its current valuation status...."
      }
    ],
    "total": 847,
    "sid": "1002833",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/dishman-carbogen-amcis-1002833"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "30-Jan-2026",
      "details": "The Company has arranged Conference Call with Investors on Wednesday 4th February 2026 at 15:00 hrs. (IST) to discuss the financial result and performance of the Company for the third quarter ended on 31st December 2025. The details of Conference Call are attached herewith.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Considering Take On Record And Approve The Un-Audited Financial Results Of The Company For The Third Quarter Ended On 31St December 2025",
      "datetime": "29-Jan-2026",
      "details": "Dishman Carbogen Amcis Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2026 inter alia to consider and approve Un-Audited Financial Results of the Company for the third quarter ended on 31st December 2025",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Allotment",
      "datetime": "20-Jan-2026",
      "details": "Pls. find attached herewith intimation of allotment of 5000 NCDs.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Dishman Carbogen Amcis Ltd has declared <strong>10%</strong> dividend, ex-date: 12 Sep 19",
          "dt": "2019-09-12",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Dishman Carbogen Amcis Technical Momentum Shifts Amid Mixed Market Signals

2025-12-03 08:08:09

Dishman Carbogen Amcis, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflecting a complex interplay of market forces. Recent evaluation adjustments indicate a transition from a sideways trend to a mildly bearish stance, underscoring the nuanced signals from various technical indicators.

Dishman Carbogen Amcis: Analytical Perspective Shifts Amid Mixed Financial and Technical Signals

2025-12-02 08:51:26

Dishman Carbogen Amcis, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market assessment following a detailed evaluation of its quality, valuation, financial trends, and technical indicators. This article explores the factors influencing the recent changes in the company’s analytical perspective, providing investors with a comprehensive understanding of its current standing.

Dishman Carbogen Amcis Technical Momentum Shifts Amid Mixed Market Signals

2025-12-02 08:11:12

Dishman Carbogen Amcis, a key player in the Pharmaceuticals & Biotechnology sector, is exhibiting a notable shift in its technical momentum as recent evaluation adjustments reflect a transition from mildly bullish to sideways trends. This development comes amid a complex interplay of technical indicators, including MACD, RSI, moving averages, and Bollinger Bands, which collectively paint a nuanced picture of the stock’s near-term trajectory.

How has been the historical performance of Dishman Carbogen?

2025-12-01 23:27:11

Revenue and Operating Performance Over the seven-year period ending March 2025, Dishman Carbogen’s net sales demonstrated a generally upward trend, increasing from ₹2,058.60 crores in 2019 to ₹2,711.50 crores in 2025. This represents a compound growth trajectory, with notable acceleration from 2021 onwards. Total operating income mirrored this pattern, reflecting the absence of other operating income throughout the period. Operating profit before depreciation, interest, and tax (PBDIT) excluding other income showed volatility. It declined from ₹551.90 crores in 2019 to a low of ₹274.35 crores in 2021, before recovering to ₹468.94 crores in 2025. Including other income, operating profit (PBDIT) followed a similar pattern, peaking at ₹605.72 crores in 2019 and dipping to...

Dishman Carbogen Sees Revision in Market Evaluation Amid Mixed Financial Signals

2025-11-28 10:04:56

Dishman Carbogen, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a nuanced shift in its financial and technical outlook. This adjustment follows a detailed reassessment of the company’s quality, valuation, financial trends, and technical indicators, offering investors a fresh perspective on its current standing.

Why is Dishman Carbogen falling/rising?

2025-11-25 01:28:44

Recent Price Movement and Market Performance Dishman Carbogen’s stock has been under pressure over the past month, registering a steep decline of 19.28%, in stark contrast to the Sensex’s modest gain of 0.82% during the same period. The one-week performance further emphasises this trend, with the stock falling 8.83% compared to the Sensex’s near-flat movement. Year-to-date, the stock is down 15.41%, while the benchmark index has advanced by 8.65%. This divergence highlights the stock’s recent struggles relative to the broader market. On the day in question, the stock underperformed its sector by 2.96%, continuing a two-day losing streak that has seen a cumulative decline of 6.68%. Intraday, the share price touched a low of ₹228.15, down 3.75%, with heavier trading volu...

Why is Dishman Carbogen falling/rising?

2025-11-07 23:37:52

As of 07-Nov, Dishman Carbogen Amcis Ltd is experiencing a decline in its stock price, currently at Rs 249.00, reflecting a decrease of Rs 18.45 or 6.9%. The stock has underperformed its sector by 6.56% today and has been on a consecutive downward trend for the last two days, resulting in a total drop of 16.2%. Additionally, the stock has shown high volatility with an intraday range of Rs 25.6 and has traded more volume closer to its low price. Despite a strong performance over the past year with a return of 29.02% and positive results in the last three quarters, including a significant increase in profits, the recent price movement indicates a struggle against short-term pressures. Broader market context shows that while Dishman Carbogen has outperformed the BSE500 over the long term, its short-term performance has been significantly weaker, with a 1-week decline of 14.65% compared to the Sensex's minor d...

Dishman Carbogen Amcis Hits Day Low at Rs 245.25 Amid Price Pressure

2025-11-07 09:42:26

Dishman Carbogen Amcis saw a notable decline on November 7, 2025, with the stock dropping significantly and reaching an intraday low. This marks a continuation of a downward trend over two days, alongside high volatility. In contrast, the broader market, represented by the Sensex, experienced a smaller decline.

Is Dishman Carbogen overvalued or undervalued?

2025-11-07 08:12:37

As of 6 November 2025, Dishman Carbogen's valuation grade has moved from very attractive to attractive, indicating a shift in market perception. The company is currently considered fairly valued. Key ratios include a PE ratio of 28.07, an EV to EBITDA of 10.39, and a Price to Book Value of 0.72. In comparison to its peers, Dishman Carbogen's PE ratio is lower than that of Sun Pharma, which stands at 35.02, and significantly lower than Divi's Lab at 79.09. However, it is on par with Cipla, which has a PE of 22.27, and Dr. Reddy's Labs at 17.42. Notably, Dishman Carbogen has outperformed the Sensex over the past year with a return of 37.05% compared to the Sensex's 3.65%, reinforcing its current valuation status....

View All News